VIRP.PA
VIRP.PA
FR0000031577
VIRBAC
Loading chart...

Company Profile

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric pheromone gel diffuser to soothe and reduce stress-related behaviors in dogs; Suigen Entero 3 is an inactivated vaccine aimed at preventing neonatal diarrhea in piglets caused by colibacillosis, clostridium, and rotavirus; Ursolyx soft chews formulated with ursolic acid that support muscle strength and mobility in dogs and cats; Zenifel a fogger and spray designed to reduce behaviors due to stress or undesirable behaviors in cats; Suigen PCV2 is a vaccine for porcine circovirus type 2; and Suigen Donoban is a multivalent vaccine used for the prevention of respiratory diseases in swine. It also provides a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, immunology, nutrition, petfood, and pharmaceutical products. In addition, the company serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.

Related stocks

GRFS
GRFS • Spain
Grifols, S.A.
7.46 USD
5.08B USD 1Y -23.1%
GRF.MC
GRF.MC • Spain
GRIFOLS S.A.
9.88 EUR
7.53B USD 1Y -21.4%
REC.MI
REC.MI • Italy
RECORDATI ORD
53 EUR
12.35B USD 1Y -1.9%
COPN.SW
COPN.SW • Ireland
COSMO N
58.7 CHF
1.22B USD
RUBICON.NS
RUBICON.NS • India
RUBICON RESEARCH LIMITED
1,548.5 INR
2.65B USD
4536.T
4536.T • Japan
SANTEN PHARMACEUTICAL CO
1,684 JPY
3.42B USD 1Y +7.8%
ORNBV.HE
ORNBV.HE • Finland
Orion Corporation B
79.6 EUR
12.52B USD 1Y +15.7%
BAYN.DE
BAYN.DE • Germany
Bayer AG N
43.77 EUR
48.19B USD 1Y +55.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
31.4% p.a.
Max Drawdown (5Y)
-50.5%
Sharpe Ratio (5Y)
-0.16
Beta Factor
0.79
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (31.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -50.5% in the extended horizon.
ende